NEW YORK (GenomeWeb News) – BG Medicine this week posted first quarter revenues of $739,000, down 17 percent from $888,000 in the first quarter of 2013.

The drop stemmed from declines in revenues from both the company's BGM Galectin-3 heart failure test and its services business. BG did $739,000 in galectin-3 sales, down 10 percent from $820,000 in Q1 2013. It posted no service revenue in the quarter, compared to $68,000 in service revenues in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.